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ABSTRACT
Transcription in eukaryotes is a multistep process
involving the assembly and disassembly of numer-
ous inter- and intramolecular interactions between
transcription factors and nucleic acids. The roles of
each of these interactions and the regions respon-
sible for them have been identified and studied
primarily by the use of mutants, which destroy the
inherent properties of the interacting surface. A less
intrusive but potentially effective way to study the
interactions as well as the surfaces responsible for
them is the use of RNA aptamers that bind to the
interacting factors. Here, we report the isolation and
characterization of high-affinity RNA aptamers that
bind to the yeast general transcription factor TFIIB.
These aptamers fall into two classes that interfere
with TFIIB’s interactions with either TBP or RNA
polymerase II, both of which are crucial for tran-
scription in yeast. We demonstrate the high affinity
and specificity of these reagents, their effect on
transcription and preinitiation complex formation
and discuss their potential use to address mechan-
istic questions in vitro as well as in vivo.
INTRODUCTION
Cellular architecture and function depend critically upon a
myriad of speciﬁc macromolecular interactions. These
include contacts involving proteins with other proteins,
nucleic acids and small molecules. Protein function has
been traditionally analyzed by inactivating or inhibiting
the protein itself using conditional and other mutations,
small molecule inhibitors (drugs), and RNAi. Since many
proteins have distinct surfaces that are responsible for
independent interactions, the ability to interfere with these
regions individually is extremely valuable in evaluating the
role of speciﬁc macromolecular interactions. Aptamers,
which are single-stranded oligonucleotides that bind with
high aﬃnity and speciﬁcity to a target molecular surface,
are well suited for this purpose (1). Aptamers are a
powerful tool for mechanistic experiments because (i) they
do not irreversibly alter the protein they bind, (ii) they
interact with and sterically block a speciﬁc surface on the
protein in much the same way as a natural interacting
partner would, and (iii) they can be expressed in a rapid
yet inducible manner in vivo, thus avoiding secondary
(plieotropic) eﬀects and allowing kinetic analysis of the
consequences of the perturbation.
RNA aptamers are isolated by a process of iterative
selection called SELEX (systematic evolution of ligands
by exponential enrichment), from a large combinatorial
starting library (2,3). The process involves repeated cycles
of binding to the target, partitioning and ampliﬁcation of
‘binders’, until high-aﬃnity aptamers are isolated.
Aptamers have been generated to bind a wide variety of
targets such as small organic molecules, peptides, proteins,
cells and even virus particles (4). They have the high
aﬃnity and speciﬁcity that is desired in drugs. Addition-
ally, they can be eﬃciently and cost eﬀectively mass-
produced as well as expressed in vivo in a functional form
in several model organisms (5).
Transcription initiation in yeast is an orchestrated event
that involves interactions of hundreds of polypeptides that
each has to be recruited to the promoter in a coordinated
andtimelymanner(6).Theprocessstartswiththeassembly
of the preinitiation complex (PIC) at the promoter (7).
TATA-binding protein (TBP) binds to the promoter
element, often as part of a bigger complex such as TFIID
or SAGA. This binding is stabilized by two general trans-
cription factors (GTFs), TFIIA and TFIIB. TFIIB
properly orients the TBP–DNA complex and facilitates
the recruitment of the RNA polymerase (Pol) II–TFIIF
complex by directly binding to Pol II (8). PIC formation is
complete with the entry of TFIIE and TFIIH, factors
involvedinpromotermeltingandopencomplexformation.
Once the PIC is assembled, DNA at the promoter is
melted, an open complex is formed and transcription
initiates. Upon transition into productive elongation,
several of the contacts established during PIC formation
are lost and new ones are made with elongation factors
that are recruited to the now elongating Pol II (9).
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interactions between the players involved. The general
transcription factors are at the heart of this interactome,
with each GTF forming a ‘node’, in contact with multiple
other factors. Our goal is to use RNA aptamers to disable
each of these ‘connections’ and thus decipher the
contribution of that interaction in the process of initiation.
In our past reports, we have described the selection of
two classes of RNA aptamers that bind to yeast TBP,
where one class interferes with the TBP–DNA interaction
and the other interferes with the TBP–TFIIA interaction
(10,11). We have also shown that while the loss of either
molecular interaction surface blocks RNA synthesis
in vitro in extracts, PIC formation is aﬀected in mecha-
nistically distinct ways (10). In this study, our focus is the
general transcription factor TFIIB. TFIIB in yeast
consists of several domains: the N-terminal Zn ribbon
domain interacts with the dock region of Pol II; the B
ﬁnger domain inserts itself into the RNA exit channel and
is in direct contact with the active site of Pol II, wherein it
inﬂuences start site selection along with Pol II and TFIIF;
the C terminal core domain consists of two imperfect
direct repeats that are responsible for TBP and DNA
binding (8,12). In addition to these contacts, TFIIB is also
thought to be a direct target of some acidic activators and
interacts with a Pol II C-terminal domain phosphatase,
Ssu72 (13,14). TFIIB is therefore central to PIC assembly,
participates in several crucial interactions and is in direct
contact with TBP.
In this article, we report the isolation and characteriza-
tion of aptamers that bind with high aﬃnity and speciﬁcity
to yeast TFIIB. We demonstrate that these aptamers are
potent transcription inhibitors in vitro that block PIC
assembly in a manner distinct from each other and either
of the TBP aptamers. We anticipate that the TBP and
TFIIB aptamers will serve as speciﬁc inhibitors to address
questions concerning basic transcription mechanisms that
have been diﬃcult to address with existing reagents.
MATERIALS AND METHODS
Plasmid constructs
The deletion constructs of yeast TFIIB (except B Finger)
were made by amplifying the appropriate regions from the
full-length clone by PCR using primers that added an NcoI
site and a 6-His tag on the N-terminal end and an XhoI
site on the C-terminal end. For the B Finger construct,
the DNA fragment encoding the Zn ribbon domain was
ampliﬁed with the addition of 50 NcoI and 30 NarI sites and
the DNA fragment encoding the core domain was
ampliﬁed with the addition of 50 NarI and 30 XhoI sites.
These were then digested with NarI and ligated ﬁrst and
subsequently digested with NcoI and XhoI to insert into
pET16b. The PCR products were then inserted into the
bacterial expression pET16b using the NcoI and XhoI (the
nucleotide positions for each of the deletion constructs
are as follows: Core, 358–1035bp; Zn, 165–1035bp; B,
1–165+358–1035; NTD, 1–267bp).
The heart muscle kinase (HMK) tag was inserted at the
C-terminal end of the core IIB construct described earlier.
First, PCR was carried out using the DNA fragment
encoding core IIB with a forward primer containing
the NcoI site and a 6-His tag and a reverse primer that did
not include the Stop codon. This was followed by a second
PCR with the same forward primer and a reverse primer
that added the HMK sequence, a Stop codon and an
XhoI site. This fragment was then inserted into pET16b
as described earlier. The sequence for the HMK tag
was obtained from (15). The constructs for TFIIB
mutants K190E, K201E, K205E and the double mutants
K190E/K201E, K201E/K205E were a gift from
Dr A. Ponticelli.
Proteinpurification
Full-length His-tagged versions of yeast TFIIB, TBP, the
deletion constructs of TFIIB and HMK-tagged core
IIB were all puriﬁed from BL21-DE3 cells according to
a standard His-tagged protein puriﬁcation protocol. The
single- and double-point mutants were puriﬁed from
JM109 cells by the same protocol. Yeast TFIIA was
puriﬁed by using a protocol obtained from S. Hahn (Fred
Hutchinson Cancer Research Center, Seattle, USA),
described earlier (11).
Invitro evolution
SELEX was carried out as described earlier (11). The
template DNA library (previously described in ref. 16)
contains on the order of 2 10
15 sequences. It consists of a
central 50-bp long randomized region ﬂanked by two
constant regions that contain the 50T7 promoter and
facilitate ampliﬁcation by PCR. RNA was made from this
DNA library by in vitro transcription with T7 RNAP and
eight rounds of selection were carried out with bacterially
expressed yeast TFIIB protein. For each cycle, the RNA
protein mixture was incubated in 1  binding buﬀer
(12mM HEPES, pH 7.9, 150–200mM NaCl, 1–10mM
MgCl2, 1mM DTT), partitioned using a nitrocellulose
ﬁlter, the bound RNA recovered by extraction with hot
phenol and ampliﬁed to yield an enriched pool for the next
cycle. The concentrations of NaCl, MgCl2 and TFIIB
were decreased gradually with each cycle to increase the
stringency of the selection. Negative selection (without
protein) was included with every cycle after the third. The
ﬁnal DNA pool was cloned into the pSTBlue-1 vector and
70 individual clones were sequenced.
Electrophoretic mobility shift (EMS)assay
RNA-binding experiments were carried using radiolabeled
RNA synthesized by internally radiolabeling RNA
(with a-P
32 UTP) during in vitro transcription by T7
RNA polymerase from the template DNA, using the
Ambion MegaShortscript kit. Radiolabeled RNA, present
at a ﬁnal concentration of 0.5nM (0.2nM in Figure 1B)
was incubated with indicated amounts of protein in 1  B
binding buﬀer (12mM HEPES, pH 7.9, 150mM NaCl,
2mM MgCl2, 1mM DTT, 5ng/ml yeast tRNA, 0.1mg/ml
BSA, 10% glycerol) for 30min at room temperature and
loaded on a native polyacrylamide gel (0.5  TBE, 6%
acrylamide with 1.5mM MgCl2 and 1mM DTT).
Complexes were resolved at 180V for 2h, gels were
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The images were scanned and analyzed with the
ImageQuant (5.2) software. EMS assays with labeled
TATA DNA were carried out as described in ref. (11).
Labeled TATA DNA was present at 0.5nM, TBP at
20nM, TFIIA at 0.5nM, TFIIB at 200nM and cold
aptamer RNAs or yeast tRNA at 800nM. For the reverse
bandshift experiment in Figures 1C and S4, the HMK-
tagged core IIB protein was radiolabeled using HMK (see
the subsequent section: ‘protease protection assay’). The
binding experiment was carried out in 1  B binding buﬀer
with 70nM core IIB and 700nM of indicated cold
aptamer RNA. The mixture was incubated for 30min
at room temperature, resolved on a 0.5 TBE, 6% native
PAGE with 1.5mM MgCl2, and processed as described
for the experiments using radiolabeled RNA.
In vitro transcription
The in vitro transcription experiments were carried out as
described in ref. (17). Yeast whole-cell extract was made
from W3031A. A plasmid template pSH515-Gless was
used which contained one Gal4-binding site, the HIS4
core promoter ( 141 to +3) and a 390-nt G-less cassette
[made by insertion of the G-less cassette from pG5MLT
into pSH515 (9) downstream of the promoter sequence].
The aptamers were added at 50nM along with the extract
and transcription was allowed to proceed for 30min for
assaying multiple-round transcription. For the single-
round experiments, aptamers were added at 50nM after
PIC formation, transcription was initiated by the addition
of NTPs for 45s, and transcription was stopped by the
addition of heparin. For the TFIIB-rescue experiments,
aptamers at 30nM and excess TFIIB at 300nM were
added along with the template to the extract.
Immobilized template assay
These experiments were carried out as described in ref.
(10). The wash buﬀer included nonspeciﬁc competitor
DNA at 10ng/ml and NP-40at 0.1% ﬁnal concentration.
Protease protection assay
C-terminally HMK-tagged core IIB protein (0.3nmol)
was radiolabeled using 2-ml HMK (5mg/ml), 5ml g-
P
32ATP (16.5pmol) in 30ml1   B binding buﬀer for 1h
at 378C. The unincorporated ATP was removed by
puriﬁcation on a P6 column (BioRAD, Hercules, CA).
Labeled core IIB measuring 7.8pmol was incubated with
78pmol of yeast tRNA (control), AptIIB-60 or AptIIB-4
RNA in 1  B binding buﬀer for 15min to allow
RNA–protein complexes to form. Partial protease diges-
tion was then carried out by addition of 300ng, 100ng,
30ng or 10ng of chymotrypsin to the mixture in a ﬁnal
volume of 10ml. After a 7-min incubation, PMSF was
added to a ﬁnal concentration of 10mM to stop the
protease digestion, SDS loading dye was added, the
samples were boiled at 958C for 3min and resolved on a
15% Tricine–SDS–PAGE overnight at 48C (18). The gel
was dried and exposed overnight on a phosphorimager
screen. Analysis of the image was done using ImageQuant
(5.2) software.
RESULTS
Selection ofRNA aptamers toyeast TFIIB
To isolate high-aﬃnity RNA aptamers that bound to
yeast TFIIB (IIB), we screened a randomized DNA library
that contains on the order of 2 10
15 random sequences
[described previously, (11,16)] by SELEX. Brieﬂy, for each
round of selection, the template DNA was transcribed
using T7 RNA polymerase to generate an RNA pool,
which was incubated with the bacterially expressed and
puriﬁed TFIIB protein. The protein-bound RNA was
partitioned away from the free RNA by nitrocellulose
ﬁltration and RNA was recovered from ﬁlter-bound
complexes by extraction with hot phenol. RNAs were
reverse transcribed and ampliﬁed to yield an enriched
Figure 1. RNA aptamers to TFIIB selected from a starting pool of
2 10
15 sequences. (A) Band shift assay with labeled RNA obtained
from the starting pool (G0), and after two (G2), ﬁve (G5) and eight
(G8) cycles of SELEX was performed with increasing concentrations of
yeast TFIIB (0, 100, 200nM). (B) Band shift assay with labeled
candidate aptamers B60 and B4 was carried out using indicated
amounts of recombinant TFIIB protein. The KD for binding was
determined to be on the order of 1nM or less. (C) Band shift assay
carried out with radiolabeled core domain of TFIIB (70nM) and
indicated cold aptamer RNA (700nM).
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Aﬃnity of the pool RNA for TFIIB was monitored by a
band shift assay with labeled RNA after every third round
of selection (Figure 1A). After eight rounds of selection,
a signiﬁcant fraction of the RNA pool bound to IIB, the
enriched DNA pool was cloned, and 70 randomly picked
clones were sequenced to identify individual candidates.
The 43 unique candidates identiﬁed were aligned by the
ClustalW multiple sequence alignment program (19) and
classiﬁed into 12 families based on sequence information.
We tested one representative member of each family
for binding to TFIIB protein and nine out of the 12
showed strong TFIIB binding activity (Supplementary
Data, Figure S1). In addition, we performed EMS assays
with each of the candidate aptamers to determine their
aﬃnity to IIB. Figure 1B shows representative EMS
experiments with two radiolabeled aptamers, AptTFIIB-4
and AptTFIIB-60. There is a single shifted band in the IIB
containing lanes that corresponds to the aptamer
RNA–TFIIB complex, and the KD calculated from the
binding curve is on the order of 1nM as measured by this
assay (Figure S2). We also determined that the aptamer
protein interaction is stable for >30min by carrying out a
similar EMS experiment in the presence of excess cold
aptamer RNA (Figure S3).
In order to assess whether the aptamers formed
conformationally distinct complexes with IIB, we per-
formed a band shift assay with the radiolabeled protein.
The core domain of TFIIB (residues 124–345) (12), was
C-terminally tagged with the HMK recognition site and
radiolabeled using recombinant HMK (Sigma, St. Loius,
MO). The labeled protein was incubated with the
indicated cold RNA aptamer in molar excess and loaded
onto a native gel (Figure 1C). Since the RNA is not
limiting in this assay, the sensitivity is higher and all forms
of RNA–protein complexes are detected. In addition, the
unbound protein is positively charged at the pH of the gel
(7.5) and therefore remains at the well unless bound to
RNA. This allows for the gel to be run much longer and
the distinct complexes are more resolved relative to a
conventional band shift assay performed with labeled
RNA. All of the RNA aptamers shown in Figure 1C are
precisely the same length (100nt) except for AptTFIIB-2,
which is 10-nt shorter (90nt); however, complexes with
distinct mobilities appear to be formed with some of these
aptamers. The overall shape of each aptamer–TFIIB
complex is determined to a large extent by the conforma-
tion(s) adopted by the RNA molecule since the protein
component is the same. Therefore, the diﬀerences in
mobilities observed could be attributed to the diﬀerences
between aptamers in their secondary and tertiary struc-
tures. However, complexes containing diﬀerent RNA
aptamers appear to have nearly identical mobility on the
native gel (B2, B3 and B9; B4 and B12). On the other
hand, complexes formed with B60 are distinct from those
with B4 and B12, and from the rest. This experiment
serves as a demonstration of a complementary approach
to characterizing aptamer–protein complexes by EMSA,
which provides information that is not obtained in a
normal
 RNA EMSA. In previous studies with TBP
aptamers from our lab [(10) and our unpublished data],
we have observed that aptamers that form complexes with
distinct mobilities on native gels (i) often bind to discrete
surfaces on the target and (ii) have disparate inhibitory
characteristics in functional assays. Taken together with
Figure 1C, these results lend support to the possibility
that these reagents may exert diﬀerent eﬀects on various
TFIIB interactions and hence aﬀect TFIIB function in
transcription in mechanistically diverse ways.
Effectof TFIIB aptamers on the TFIIB–TBP interaction
In eukaryotic mRNA transcription, TBP nucleates the
assembly of PIC formation by binding to DNA at the
promoter (6). TFIIB is then thought to bind and stabilize
the TBP–DNA interaction as well as facilitate Pol II
recruitment via its N-terminal domain (20). Because the
contacts with TBP and Pol II are functionally the most
important of TFIIB’s interactions, we set out to determine
if the TFIIB aptamers interfered with either of these
interactions.
We tested the TFIIB aptamers both for their abilities to
interfere with the formation of a TFIIB–TFIIA–TBP–
TATA (DAB) complex assembled in vitro and to disrupt a
preformed complex. Native gel conditions that are
required to visualize the TFIIB–TBP–DNA (DB) complex
do not resolve the TBP–DNA complex as distinct from the
larger complex; therefore, TFIIA, which stabilizes
the TBP–DNA interaction but does not appear to aﬀect
the TFIIB–TBP interaction directly in any manner (21),
was included to overcome this technical limitation (the
TFIIB aptamers do not bind to TFIIA or to TBP, data
not shown). First, the direct ‘competition’ experiment was
designed to reveal if the aptamer interfered with the
formation of the quaternary complex (DAB). The reaction
was allowed to proceed to equilibrium and complexes
were resolved by native PAGE. Figure 2A shows that in
the presence of a molar excess of cold RNA aptamer (over
IIB), some of the aptamers interfere with formation of the
DAB complex but not the DA complex. These results
indicate that these aptamers are able to compete with TBP
for binding to IIB. All of the tested aptamers except
AptTFIIB-4, 9, 12 and 27, and the control tRNA, were
able to compete to a large extent. Based on their ability to,
or not to, interfere with the TBP–TFIIB interaction we
divided these RNA aptamers into two functionally distinct
classes.
The second assay was a ‘disruption’ experiment, which
allowed us to assess whether the aptamers that do interfere
with this interaction could only do so passively by
competition or if they were able to actively dislodge the
competitor from a preformed complex. DAB complexes
were ﬁrst assembled on TATA DNA and allowed to reach
equilibrium. A molar excess of RNA aptamer or control
yeast tRNA was added subsequently to the complex and
the reaction was immediately loaded on a native gel
and resolved. The stability of the DAB complex was
also simultaneously assayed by incubating the complex
in the presence of excess cold DA for increasing amounts
of time. In this instantaneous ‘disruption’ experiment
(Figure 2B), it was clear that all the aptamers that were
able to compete were also able to instantaneously disrupt
Nucleic Acids Research, 2008, Vol. 36, No. 9 3121the TFIIB–TBP interaction and remove TFIIB from
the complex. It is also apparent that this disruption
could not be explained by the instability of TFIIB binding
because incubation with excess cold DA for the same
amount of time did not lead to a loss of TFIIB from the
DAB complex. Thus, the TFIIB aptamers fall into two
classes—class I includes the majority of the aptamers
(such as AptTIIB-60) which interfere with the TFIIB–TBP
interaction and class II aptamers (such as AptTFIIB-4)
which bind with comparable aﬃnity, but do not aﬀect this
interaction.
Because the class II aptamers do not interfere with the
TBP–TFIIB interaction, they would be expected to bind
this complex. The smears seen between the DA and DAB
complex in the lanes containing the class II aptamers in
Figure 2A and B could contain a faster moving, RNA
containing DAB–aptamer complex, as seen previously
with other RNA–protein interactions (22). However, we
were unable to detect a new distinct band corresponding
to this new DAB–RNA complex in our experiments
(Figures 2A and S7). Additionally, it is evident that the
class I aptamers not only bind with high aﬃnity but are
also able to dramatically disrupt a physiological TBP
interaction as a consequence of this binding. This property
of the aptamers makes them very valuable inhibitors for
use in a physiological setting, because a large proportion
of TFIIB in the cell likely resides in macromolecular
assemblies (and not as a free entity in solution), in which
case a passive competitor would be unable to eﬀect this
inhibition.
The TFIIB aptamers inhibit transcription, in vitro
The TFIIB–TBP interaction is believed to be essential for
PIC formation and therefore for transcription by Pol II.
Therefore, the class I aptamers that disrupt this interac-
tion when a complex is assembled from puriﬁed proteins,
would be expected to prevent Pol II transcription, if they
were functional in the context of a complex milieu of
proteins such as a whole-cell extract. To test this, we
performed an in vitro transcription assay using a plasmid
template, which contained Gal4-binding sites and the
yeast HIS4 promoter followed by a G-less cassette, in the
presence of whole-cell extract from Saccharomyces cere-
visiae (yeast). Aptamer RNA, or control yeast tRNA (or
G0 RNA, Figure S6) was added to the extract along with
the template (Figure 3A) or after PIC formation
(Figure 3B), mimicking the competition and disruption
experiments described above [the aptamers are stable in
the whole-cell extract in the presence of RNase Inhibitor
SuperaseIn (Ambion, Austin, Texas), for the duration of
the experiment, data not shown]. Transcription was
initiated by the addition of a nucleotide mix containing
one radiolabeled NTP and allowed to proceed for 30min
(multiple rounds, Figure 3A) or 45s (single round,
Figure 3B). The radiolabeled transcript synthesized was
run out on a denaturing gel and analyzed. The large
reduction in the intensity of the bands corresponding to
the full-length transcript in every lane that contained
aptamer RNA, in both of these experiments, leads to the
following conclusions: (i) that all the aptamers, irrespec-
tive of whether they are class I or class II, inhibit
transcription both when added before (Figure 3A) as
well as after PIC formation (Figure 3B); and (ii) they
Figure 2. The TFIIB aptamers fall into two classes based on their
ability to interfere with TFIIB–TBP interaction. (A) Complexes were
assembled on labeled TATA DNA with yeast TBP (20nM), TFIIA
(0.5nM) and TFIIB (200nM) in the presence or absence of the TFIIB
aptamers (800nM). Class I aptamers (B2, B60, etc.) compete eﬀectively
and prevent formation of the TATA–TBP–TFIIA–TFIIB (DAB)
complex, whereas Class II aptamers (B4, etc.) were not as eﬃcient.
The lighter band seen migrating slightly faster than the DAB complex
in the ytRNA lane is most likely due to dissociation of the complex
during electrophoresis. (B) The Class I aptamers instantaneously
disrupt the preformed DAB complex by removing TFIIB (leaving the
DA complex intact), whereas the Class II aptamers had no such eﬀect.
The ‘yt’ represents a yeast tRNA which is used as a control RNA. In
the lanes marked by the box, excess cold DA was added to the DAB
complex to verify that the DAB complex is stable for the time frame of
the disruption and competition experiments.
Figure 3. The TFIIB aptamers inhibit basal transcription in vitro from
a Pol II promoter in a yeast whole-cell extract. (A) The aptamers were
added at 50nM along with the extract to a plasmid template containing
the HIS4 promoter fused to a G-less cassette and transcription was
allowed to proceed for 30min. The correct transcripts are indicated
(asterisks). (B) Aptamers were added at 50nM after PIC formation,
and single-round transcription was assayed by incubating with NTPs
for 45s, and transcription was stopped by the addition of heparin.
(C) Transcription inhibition with the aptamers at 30nM (lanes 3 and
5), (hatched bars) and with addition of recombinant yeast TFIIB (lanes
2, 4 and 6) to the extract (black bars) were quantiﬁed and plotted.
Excess TFIIB was able to completely restore transcription in the
presence of the aptamers.
3122 Nucleic Acids Research, 2008, Vol. 36, No. 9appear to work in the context of an extract very eﬃciently
at only 2–3  molar excess of their target (TFIIB
concentration in the reaction mix  20nM as determined
by western analysis, data not shown). In order to conﬁrm
that this inhibition was because of the aptamers acting
through TFIIB and not an indirect eﬀect of addition of
exogenous RNA, two controls were performed. First,
addition of yeast tRNA or G0 RNA (Figure S6) at a
similar concentration did not inhibit transcription in any
experiment (Figures 3A and B, and S6). Second, when the
extract was supplemented with molar excess of recombi-
nant TFIIB, prior to addition of aptamer RNA (or after
aptamer addition, Figure S6), transcription activity was
unaﬀected (Figure 3C). For the experiment in Figure 3C,
the aptamers were used at 30nM (not 50nM as in
Figure 3A and B) so as to enable add-back of exogenous
TFIIB at 300nM (which is the maximum TFIIB that
could be added without any signiﬁcant eﬀect on the
control lanes). The inhibitory eﬀect of B4at this concen-
tration is slightly less than when added at 50nM. The fact
that excess TFIIB is able to suppress the transcription
inhibition mediated by the aptamer supports the idea that
the transcription inhibition observed in the presence of the
aptamer is due to the unavailability, speciﬁcally, of TFIIB,
because when excess TFIIB is provided, this inhibition is
reversed.
In conclusion, the RNA aptamers are eﬀective inhibi-
tors of Pol II driven transcription in a yeast whole-cell
extract. However, given their distinct eﬀects on DAB
complex formation, it seems likely that the mechanism of
the inhibition achieved is diﬀerent for each aptamer class.
Aptamers affectPICformation at discrete steps
To evaluate the mechanistic diﬀerences among the
diﬀerent classes of aptamer RNAs, we devised an
immobilized promoter template assay to monitor PIC
assembly in the presence of each of the representative
aptamers (AptTFIIB-4 and AptTFIIB-60). A DNA
template containing the HIS4 promoter and Gal4-binding
sites was immobilized onto magnetic beads and PICs were
assembled on the promoter using yeast whole-cell extract
as a source for transcription machinery. The unbound
proteins were then washed away and the composition of
the assembled PIC was ascertained by SDS–PAGE and
western analysis. Occupancy of four components of the
PIC, namely, TBP, TFIIB, TFIIA and Pol II were
monitored using speciﬁc antibodies. When a class I
aptamer such as B60 was added along with the extract
to the template, PIC formation appeared to be severely
compromised (Figure 4). TBP and TFIIA levels at the
promoter were not aﬀected signiﬁcantly throughout
the range of aptamer concentrations explored; however,
even at the lowest aptamer concentration, TFIIB and
Pol II were reduced to undetectable levels. This is
consistent with the observation that B60 interferes with
the TFIIB–TBP interaction. Therefore, in the presence of
B60, TBP and TFIIA assemble at the promoter, but
TFIIB, which is now in complex with B60, is unable to do
so. Also, because the N-terminal domain of TFIIB,
speciﬁcally the Zn ribbon, is known to be required to
recruit Pol II (8) to the PIC, the absence of TFIIB results
in a loss of Pol II recruitment at the promoter.
In the presence of AptTFIIB-4, a class II aptamer,
TFIIB occupancy at the PIC is nearly unchanged, as are
TBP and TFIIA levels, even at the highest aptamer
concentration tested (Figure 4). Nonetheless, the level of
Pol II at the promoter decreased proportionally with
increasing aptamer concentration, suggesting that B4
binds to TFIIB and this binding aﬀects the TFIIB–Pol
II interaction. Thus, although both classes of aptamers
result in the same ‘phenotype’ i.e. transcription inhibition,
they do so by disconnecting discrete links in the
transcription circuit.
Proteasefootprinting reveals the contactsites
ofthe aptamers on TFIIB
The stark diﬀerence in the way the two classes of aptamers
inhibited PIC formation lead to the possibility that they
Figure 4. Pre-initiation complex (PIC) formation at the HIS4 promoter
was monitored in an immobilized template assay. Bead bound
templates were incubated with yeast whole-cell extract in the presence
of the TFIIB aptamers B60 or B4 at 50nM for 30min. The templates
were then washed and promoter bound factors were analyzed by
western blots using speciﬁc antibodies [anti-TFIIB, anti-Rpb3 (PolII),
anti-TBP and anti-Toa2 (TFIIA)]. The results were quantiﬁed and the
values normalized to the no aptamer sample are plotted. Error bars
represent the SEM for three independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 9 3123might bind to distinct molecular surfaces on TFIIB. In an
attempt to map the region of the protein bound by each of
these aptamers, we generated a series of deletions in yeast
TFIIB. Figure 5A illustrates these deletions in the Zn
ribbon (Zn), B ﬁnger (B), Zn ribbon and B ﬁnger
(core) and the core domain (NTD). All the puriﬁed
Escherichia coli expressed proteins except the core domain
deletion bound AptTFIIB-4 as well as AptTFIIB-60 with
aﬃnity (KD) similar to that of full-length TFIIB
(Figure 5A). Thus, the binding site for both of the
aptamers (and that of all the other aptamers mentioned
previously in this study, data not shown) resides in the
core domain of TFIIB (the minimal domain tested).
Protease footprinting provided a higher resolution
mapping. This technique has previously been used to
map protein–protein interaction sites (15,23). The diges-
tion of an end-labeled protein with limiting amounts of a
speciﬁc protease gives rise to a pattern of bands
corresponding to the cleavage products. The protection
of a protease site by another factor (protein or RNA)
obscures access of the protease and causes the reduction in
the intensity of the corresponding band(s).
The core domain of TFIIB was C-terminally tagged
with the HMK recognition site and radiolabeled using
recombinant HMK (Sigma). This protein was allowed to
bind to each of the aptamers or yeast tRNA as a control,
Figure 5. Deﬁning the RNA aptamer contact sites on TFIIB. (A) Bandshift assay with the full length (F), core domain (C), delta Zn ribbon (Zn)
and delta B-ﬁnger (B) versions of yeast TFIIB. The labeled aptamer RNA ( 1nM) was incubated with the indicated protein (50nM) and loaded
on a native gel. Schematic showing the deletion constructs used in the experiment. (B) C-terminally kinase-labeled core domain of TFIIB (0.6 uM)
was subjected to digestion with increasing amounts of chymotrypsin in the presence of aptamers B4 or B60 or yeast tRNA (3uM) for 7min. Products
were resolved on a Tricine–SDS 15% polyacrylamide gel. Asterisk indicates the region where protection is seen in the presence of the aptamers. (C)
Bandshift assay with the two double mutants, K190E K201E and K201E K205E, as well as wt yeast TFIIB. Labeled B60 or B4 RNA was incubated
with indicated amounts of the mutant or wt yeast TFIIB for 30min and loaded on a native gel. (D) Bandshift assay with K190E, K201E and K205E
as well as wt TFIIB. Labeled B4 or B60 was incubated with indicated amounts of each protein for 30min and loaded on a native gel. Graphs are
plotted as % of total counts bound to protein (n=2).
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V8 protease, Figure S5) and analyzed by high-resolution
Tricine–SDS–PAGE (we ensured that all of the protein
was RNA-bound, Figure S4). Sites on the protein that
were bound by the aptamer were protected from digestion
and did not give rise to bands on the denaturing gel. There
were several distinguishable bands corresponding to cut
sites on core IIB, the most predominant of these
corresponded to the linker region that connected the two
direct repeats within the core (Figure 5B) (a similar
experiment carried out with 350nM aptamer RNA and
70nM labeled TFIIB shows comparable protection
pattern, data not shown). Surprisingly, in the presence
of either aptamer, the pattern was remarkably similar—
showing protection at residues just preceding the linker
region on the ﬁrst direct repeat. A stretch of basic residues
in the last two helices of the ﬁrst repeat of the core domain
(helices D1 and E1) provide potential targets for RNA
interactions.
Previously, mutations of speciﬁc lysine residues in these
last two helices of the ﬁrst repeat (K190, K201 and K205)
have been shown to aﬀect basal (in yeast) or activated (in
human) Pol II transcription (24,25). Therefore, we tested
the ability of the aptamers to bind to double mutant
IIB with each pair of lysine residues mutated to glutamic
acid (K190E, K201E and K201E, K205E). In the EMS
assay shown in Figure 5C, neither aptamer was able to
bind any of the mutants indicating that both aptamers
indeed contacted this region within the core domain of
TFIIB (the double radical substitution mutants are
properly folded and support partial basal transcription
from a whole-cell extract in vitro, Figure S6). Overall, it
appeared that both classes of aptamers contacted at least a
few of the same residues in the core domain. However,
when we carried out binding assays with the single
mutants in the same region (K190E, K201E and
K205E), we observed diﬀerences in the binding character-
istics of the two aptamers. While B4 is unable to bind well
to all three single mutants, B60 appears to be severely
compromised in forming a complex mainly with the
K201E mutant (Figure 5D). Because the B4 and B60
aptamers are at least as big as the protein in overall size,
we propose that they both depend on contact with the end
of the ﬁrst repeat in the core IIB, but the molecular
interaction surface for each aptamer–protein complex is
likely to be distinct, leading to their diﬀerential eﬀects on
TFIIB containing complexes.
DISCUSSION
RNA aptamers have been selected using SELEX proce-
dures to bind a variety of protein targets, the vast majority
made with therapeutic applications in mind (26–30).
However, with this study and our previously published
studies (10,17,31), we are illustrating the potential of
these reagents as tools to probe macromolecular interac-
tions in basic research as well. These RNAs can bind with
high aﬃnity to a protein surface and thereby eﬀectively
prevent speciﬁc interactions of that surface with other
particular proteins or nucleic acids. This allows the
assessment of that interaction without necessarily inter-
fering with the overall integrity of the targeted protein or
its other interaction surfaces. Our goal is to develop a
collection of highly speciﬁc reagents targeting key
regulatory transcription factors to dissect the role of
particular factor interactions in transcription and its
regulation both in vitro and in vivo.
Here, we isolate and characterize RNA aptamers
that bind to yeast general transcription factor TFIIB.
Although several families of aptamer RNAs were isolated,
we have focused mainly on two representative molecules,
B60 and B4. These aptamer RNA molecules display
extremely high aﬃnity to their target with dissociation
constants (KD)o f<1nM. We believe that extensive
protein–RNA interaction interfaces, as well as a stable
RNA structure, contribute to this high aﬃnity. It has
previously been observed that sequences with higher
information content, as judged from the complexity of
the structure of these folded RNAs, tend to be the ones
with the highest aﬃnity to the target (32). In agreement
with this, many of the aptamers isolated in the selection
appear to include three-way junctions and pseudoknots
in their secondary and tertiary structure as predicted by
the RNA structure prediction program, Kinefold (33).
Although high-aﬃnity aptamers do not guarantee a
high degree of speciﬁcity in binding to small molecules
(34), this is the exception rather than the rule with protein-
binding aptamers. The speciﬁcity arises from the extensive
contacts that the RNA makes on the structured surface of
the protein, which is unlikely to be duplicated exactly in
another unrelated protein (25). In the case of the TFIIB
aptamers, we know that B60 as well as B4 are unable
to bind to human TFIIB, which is about 80% similar to
the yeast TFIIB in its C terminal domain. The region on
the protein that is contacted by the RNAs is highly
conserved in both yeast and human TFIIB, but this region
alone is probably not suﬃcient for aptamer binding. The
RNA molecules, which are reasonably large ( 30kDa),
recognize a molecular ‘surface’, only a part of which is
highly conserved, and the entire surface is not identical
in the two orthologs. The fact that a large molecular
surface is probably buried in the RNA–protein complex
then provides the basis for the spectacular aﬃnity and
speciﬁcity of this interaction. An additional proof for this
speciﬁcity comes from the observation that we are able to
reverse the aptamer-mediated inhibition of transcription
from extracts in vitro by addition of molar excess of
recombinant TFIIB.
Aptamers, in general, tend to bind to the functionally
important epitopes on the target. TFIIB makes crucial
contacts with TBP as well as Pol II, and so the surfaces
involved in these interactions are the important ‘func-
tional’ epitopes in the protein. From the protease mapping
experiments, we ﬁnd that both aptamers contact a helix
located at the end of the ﬁrst repeat in the core domain
of TFIIB. This region contains a high density of positively
charged residues on one face of the helix, which explains
why it seems to be a preferred nucleic acid-binding site.
Interestingly, although both B60 and B4 aptamers have a
common region of contact they interfere in distinct
ways with the formation of the PIC with B60 blocking
Nucleic Acids Research, 2008, Vol. 36, No. 9 3125TFIIB’s binding to TBP and B4 blocking interaction with
Pol II. This common region in the TFIIB core domain is
also adjacent to the linker that connects the two repeats in
the core, and has been shown to inﬂuence the ‘closed’
to ‘open’ conformational change that is required for
hTFIIB incorporation into the PIC (8,35). This suggests
that RNAs that bind in the vicinity of the linker could
interfere with TBP or Pol II binding directly by steric
hindrance. Alternatively, they could also aﬀect TFIIB
conformation and therefore indirectly inﬂuence one or
both functional interactions. We favor the former model
because the pattern of protease cleavage of IIB is altered
in a very localized manner by addition of either RNA
aptamer.
Another remarkable property of these RNAs is their
ability to disrupt a preformed complex containing TFIIB,
be it a TFIIB–TBP–TATA complex assembled from
puriﬁed proteins or a complete PIC formed in the context
of a whole-cell extract, with multiple other proteins in
contact with TFIIB. We have observed this property
in some of our TBP aptamers as well (11). This is an
especially important feature for any reagent meant for use
in vivo as all of the target protein cannot be expected to be
freely available in solution for binding. At least in one
case, with AptTBP-12, trimming the RNA sequence can
lead to a selective loss of just the ability to disrupt (our
unpublished data) complexes making the aptamer a
passive competitor. It is therefore tempting to speculate
that the structured RNA uses one of its ‘arms’ as a
foothold to bind ﬁrst to an exposed surface on the target
and subsequently gain access to the ‘functional’ epitope
that forms the higher-aﬃnity binding site.
Finally, the fact that the RNA aptamers are eﬀective in
whole-cell extracts from yeast bodes well for their
application in vivo. In the future, we plan to express
these RNAs in a regulated manner in vivo in yeast to
quantitatively inhibit PIC formation at speciﬁc stages.
The use of the four classes of aptamers that target the
TBP–DNA, TBP–TFIIA, TFIIB–TBP and TFIIB–PolII
interactions speciﬁcally will allow us to dissect the role of
each of these contacts in the transcriptional program
of yeast.
From previous studies, we know that RNA aptamers
can be produced in a controlled manner in vivo by
constructing regulated genes encoding the aptamer RNAs
and expressing them in a cell type and developmental
stage-speciﬁc manner in higher eukaryotes as well (31,36).
These RNAs can then selectively inhibit a speciﬁc
surface on the target protein rapidly and completely
in vivo, and the consequences can be assayed almost
immediately at the genomic level. We hope that this
strategy will prove to be generally applicable and provide
a ﬁner tool to dissect the complex network of macro-
molecular interactions that are key to transcription
initiation as well as other cellular processes in higher
organisms.
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